Výsledky vyhledávání - "Felice P. Lin"

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib

Autor: Jerald P. Radich, Solveig G. Ericson, Daniel J. DeAngelo, Carole B. Miller, Ghulam Warsi, Felice P. Lin, Sikander Ailawadhi, Luke P. Akard, Anand Jillella

Publikováno v: Therapeutic Advances in Hematology. 8:3-12

Background: The phase II, exploratory, open-label Exploring Nilotinib BCR-ABL Effects (ENABL) study [ ClinicalTrials.gov identifier: NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chron

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a887ed9c7737007000945f1d39a9d97d
https://doi.org/10.1177/2040620716678118

Zobrazit plný text záznamu

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

Autor: Felice P. Lin, Jorge E. Cortes, Carole B. Miller, Ghulam Warsi, Lambert Busque, Jeffrey H. Lipton, Christopher Hunt Keir, Michael J. Mauro, Javier Pinilla-Ibarz, Luke P. Akard

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 16(5):286-296

Background Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment adherence, which is associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ace529a0f781ae8d68f4c20ada8ea6

Zobrazit plný text záznamu

Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Autor: Carole Paley, Michael R. Savona, Ghulam Warsi, Jerald P. Radich, Rebecca B. Klisovic, Michael J. Mauro, Rosalind Catchatourian, Harry P. Erba, Ellen K. Ritchie, Ilva Dautaj, Michael W. Deininger, Felice P. Lin

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 16:S63

Background: Clinical studies have shown that some pts with CML-CP who achieve deep, sustained molecular response (MR) on BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy are able to stop treatment and maintain treatment-free remission (TFR). Because

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6acba4e8b099f5d448eebb5955732c5
https://doi.org/10.1016/j.clml.2016.07.091

Zobrazit plný text záznamu

Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Autor: Ellen K. Ritchie, Rosalind Catchatourian, Rebecca B. Klisovic, Michael W Deininger, Harry P. Erba, Jerald P. Radich, Michael R. Savona, Ghulam Warsi, Carole S. Paley, Ilva Dautaj, Felice P. Lin, Michael J. Mauro

Publikováno v: Blood. 126:4050-4050

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd9c02b0b92ae7da0ca25445d43675fd
https://doi.org/10.1182/blood.v126.23.4050.4050

Zobrazit plný text záznamu

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Autor: Sikander Ailawadhi, Jeffrey H. Lipton, Carole B. Miller, Michael J. Mauro, Javier Pinilla-Ibarz, Luke P. Akard, Felice P. Lin, Jorge E. Cortes, Solveig G. Ericson

Publikováno v: Blood. 120:3782-3782

Abstract 3782 Background: A large number of Ph+ CML pts treated with IM experience mild to moderate AEs that can negatively impact QoL. A recent study (Efficace F et al. Ann Hematol. 2012) reported that pts and healthcare professionals ranked several

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::58ce8edb43b2db718e154b604ae3e541
https://doi.org/10.1182/blood.v120.21.3782.3782

Zobrazit plný text záznamu

Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update

Autor: Javier Pinilla-Ibarz, Jeffrey H. Lipton, Luke P. Akard, Solveig G. Ericson, Lambert Busque, Sikander Ailawadhi, Michael J. Mauro, Carole B. Miller, Felice P. Lin, Jorge E. Cortes

Publikováno v: Journal of Clinical Oncology. 30:6605-6605

6605 Background: This study update assesses change in chronic LG non-heme AEs in adult Ph+ CML-CP pts switched from IM to NIL. Methods: Pts were eligible if treated with IM 400 mg/d for ≥3 mo, and had IM-related grade (G) 1/2 non-heme AEs persistin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::426197101f830fae256890aef9fcbbbe
https://doi.org/10.1200/jco.2012.30.15_suppl.6605

Zobrazit plný text záznamu

Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib

Autor: Jerald P. Radich, Stuart L. Goldberg, Sikander Ailawadhi, Carole B. Miller, Anand Jillella, Denise Williams, Daniel J. DeAngelo, Luke P. Akard, Felice P. Lin

Publikováno v: Blood. 116:2301-2301

Abstract 2301 Background: Nilotinib is a potent, highly selective Bcr-Abl kinase inhibitor approved for adult patients with Ph+ CML in chronic and accelerated phase who are resistant or intolerant to IM and for frontline CML treatment. The achievemen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::787ba7389f86c53f3434e7d46adfc3a2
https://doi.org/10.1182/blood.v116.21.2301.2301

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání